Transwell assays and wound-healing assays indicated that the Akt activator enhanced HCC cell migration and invasion ability in Hep3B and SMMC-7721 cells transfected with DCAF1-shRNA (Fig. 6E-F, S4A-B), while the Akt inhibitor suppressed cell migration and invasion in HepG2 cells overexpressing DCAF1 (Figure S4A-B). Here, AKT1 is linked to hepatocellular carcinoma.